Vol 14, No 4 (2010)
Editorial
Published online: 2010-10-14
Will new antihypertensive drugs emerge? Part 1
Anna Wolska-Bułach, Lucyna Woźnicka-Leśkiewicz, Jerzy Głuszek
Nadciśnienie tętnicze 2010;14(4):235-252.
Vol 14, No 4 (2010)
Artykuły redakcyjne
Published online: 2010-10-14
Abstract
Even though there are numerous hypotensive preparations
available on the market, the effectiveness of the therapy of
arterial hypertension is still highly unsatisfactory. The effectiveness
of the therapy would certainly be enhanced by the
introduction of new antihypertensive drugs. Our work outlines
currently-studied pathophysiological mechanisms, knowledge
of which may improve synthesis and introduce new hypotensive
drugs into the pharmaceutical market. We further describe
innovative chemical compounds that have a chance to expand
the pharmacological potential of the arterial hypertension
therapy in the near future. In particular, the research briefly
presents compounds that demonstrate the agonist-like activity
to angiotensin 1–7, inhibiting biosynthesis or blocking
endothelin receptors and inhibitors of the cerebral aminopeptidase
and vascular oxidase. Finally the research introduces new
preparations that open the potassium channel and release nitric
oxide. The second part of the work briefly outlines the study of
the compounds demonstrating a simultaneous effect on two
metabolic pathways leading to the reduction of blood pressure.
For example, preparations that have a simultaneous effect on
both, the angiotensin converting enzyme and the natriuretic
peptide synthesis, or drugs from the calcium antagonists group,
which inhibit both the L-type and T-type calcium channels.
The described preparations are at different stages of the pharmacological
and clinical studies; however, it may be expected
that at least some of them will be applied in the therapy of
arterial hypertension in the relatively near future.
Arterial Hypertension 2010, vol. 14, no 4, pages 235-252.
Abstract
Even though there are numerous hypotensive preparations
available on the market, the effectiveness of the therapy of
arterial hypertension is still highly unsatisfactory. The effectiveness
of the therapy would certainly be enhanced by the
introduction of new antihypertensive drugs. Our work outlines
currently-studied pathophysiological mechanisms, knowledge
of which may improve synthesis and introduce new hypotensive
drugs into the pharmaceutical market. We further describe
innovative chemical compounds that have a chance to expand
the pharmacological potential of the arterial hypertension
therapy in the near future. In particular, the research briefly
presents compounds that demonstrate the agonist-like activity
to angiotensin 1–7, inhibiting biosynthesis or blocking
endothelin receptors and inhibitors of the cerebral aminopeptidase
and vascular oxidase. Finally the research introduces new
preparations that open the potassium channel and release nitric
oxide. The second part of the work briefly outlines the study of
the compounds demonstrating a simultaneous effect on two
metabolic pathways leading to the reduction of blood pressure.
For example, preparations that have a simultaneous effect on
both, the angiotensin converting enzyme and the natriuretic
peptide synthesis, or drugs from the calcium antagonists group,
which inhibit both the L-type and T-type calcium channels.
The described preparations are at different stages of the pharmacological
and clinical studies; however, it may be expected
that at least some of them will be applied in the therapy of
arterial hypertension in the relatively near future.
Arterial Hypertension 2010, vol. 14, no 4, pages 235-252.
Keywords
hypertension; MAS receptor; ETA receptor; AT1 receptor; angiotensin 1–7; multi-target drugs; ACE; ECE; NEP; nitric oxide releasing drug
Title
Will new antihypertensive drugs emerge? Part 1
Journal
Arterial Hypertension
Issue
Vol 14, No 4 (2010)
Article type
Editorial
Pages
235-252
Published online
2010-10-14
Page views
844
Article views/downloads
2982
Bibliographic record
Nadciśnienie tętnicze 2010;14(4):235-252.
Keywords
hypertension
MAS receptor
ETA receptor
AT1 receptor
angiotensin 1–7
multi-target drugs
ACE
ECE
NEP
nitric oxide releasing drug
Authors
Anna Wolska-Bułach
Lucyna Woźnicka-Leśkiewicz
Jerzy Głuszek